KPV Dosage Chart: Oral vs Injectable, Studied Doses

Key takeaways

• There is no human dose of KPV, because there is no human study of KPV: no trial has been published or registered as of October 2026. Every KPV dosage chart online is a seller's invention.
• The studied doses are in mice, rabbits and cell cultures: 100 micromolar KPV in mouse drinking water (about 34 mg per liter), 16 mcg/kg a day of KPV packaged in colon-targeted nanoparticles, a single 1 mg/kg injection in a mouse brain-injury model, 1 to 10 mg/mL eye drops in rabbits, and 10 nanomolar in human gut cells.
• Seller charts list 250 to 500 mcg capsules, 500 to 1,500 mcg a day by nasal spray and 200 to 500 mcg by injection. Scaled from the drinking-water studies, a human-equivalent intake would be about 30 to 40 mg a day by surface area or 380 to 480 mg a day by weight, our arithmetic, not a dose; the capsule figures are 60 to 160 times lower.
• Oral KPV is plausible because the peptide rides a transporter, PepT1, that is switched on in an inflamed colon. Plausible is not tested: the same laboratory found free KPV needed roughly 12,000 times the concentration of nanoparticle-packaged KPV, and no capsule is a nanoparticle.
• No US pharmacy may compound KPV, so there is no pharmacy label and no reconstitution example on this page. The July 2026 committee vote changed nothing until FDA publishes a rule.

The direct answer: there is no KPV dose for humans, oral or injectable, because KPV has never been studied in a human. No clinical trial has been published, none is registered, and FDA's own reviewers said in July 2026 that the human data do not exist. What does exist is a small set of mouse, rabbit and cell-culture doses, which this page lays next to the charts that sellers circulate, with our conversions labeled as the arithmetic they are. Our KPV profile covers the mechanism, the evidence and the legal status in full, and our KPV versus BPC-157 comparison deals with the gut-healing question the two peptides are usually sold for together.

The studied doses

Three things stand out. The oral studies did not dose by weight at all; the mice simply drank a fixed concentration, so any milligram-per-kilogram figure is already an estimate. The nanoparticle work shows that how the peptide is packaged changes the effective amount by orders of magnitude. And the only injected dose, 1 mg/kg, is a one-time neuroprotection experiment, not a dosing study.

The charts sellers circulate

A number without a source is still a number, and the charts are internally consistent arithmetic: a 5 mg vial in 2 mL gives 2.5 mg/mL, so 250 mcg is 0.1 mL. The reconstitution calculator will reproduce that for any vial, and the arithmetic is the only part of a chart that can be checked. We do not give a worked reconstitution example for KPV, because no pharmacy label exists to check it against and no legal product exists to reconstitute.

Our arithmetic, labeled as arithmetic

These conversions show how far the charts sit from the studies. None of them is a dose.

• Drinking water to milligrams per kilogram. KPV has a molecular weight of about 342, so 100 micromolar is about 34 mg per liter, or 34 micrograms per milliliter. A 25-gram mouse drinks roughly 4 to 5 mL a day, which is 140 to 170 micrograms of KPV a day, or about 5.5 to 7 mg per kilogram a day. Sick mice drink less, so the real intake was probably lower.
• Mouse to human. Scaled by body weight to a 70-kilogram adult, 5.5 to 7 mg/kg is roughly 380 to 480 mg a day. Scaled by body surface area, the method FDA's guidance uses to estimate first-in-human doses (divide the mouse mg/kg figure by about 12.3), it is about 30 to 40 mg a day. A 250 to 500 mcg capsule sits 60 to 160 times below the surface-area figure and 760 to 1,900 times below the weight figure.
• The nanoparticle dose. 16 mcg/kg a day becomes about 1.1 mg a day by weight or about 90 mcg a day by surface area, which is in the range the capsule charts quote. But that dose was of KPV packaged in a hyaluronic-acid nanoparticle inside a hydrogel that releases in the colon, a formulation the same laboratory found to be thousands of times more potent than free peptide. A capsule of free KPV at that dose is not that experiment.
• The injected dose. 1 mg/kg becomes 70 mg by weight or about 5.7 mg by surface area, roughly 10 to 350 times the 200 to 500 mcg on seller charts, and it was given once.

The honest reading is that the seller charts match no study under any scaling. They are not a cautious fraction of the mouse dose and not an extrapolation from the nanoparticle dose; they are the BPC-157 numbers reused. Even a chart that did track the mouse data would still be guesswork, because the question that matters, how much KPV reaches an inflamed human colon or a patch of skin after a capsule, a spray or an injection, has never been measured in anyone.

Why oral KPV is plausible, and why that is still not evidence

Most peptides are digested in the stomach and small intestine, which is why so many are sold as injections. KPV is different in one respect: it is a tripeptide, and the small intestine has a dedicated transporter, PepT1, for absorbing dipeptides and tripeptides from food. The Emory group showed that KPV is a PepT1 substrate, that it inhibits NF-kappa-B inside colon and immune cells at 10 nanomolar, and that PepT1, normally almost absent from the colon, is switched on in the colon lining during inflammatory bowel disease (Dalmasso 2008). In a later study, KPV in drinking water prevented colitis-associated tumors in normal mice and did nothing in mice without PepT1 (Viennois 2016). So the oral route has a mechanism, and it is specific: an inflamed colon has the transporter, a healthy colon largely does not.

Plausible is where it stops. No human pharmacokinetic study of KPV exists, so nobody knows how much of a swallowed capsule survives the stomach, how much is absorbed in the small intestine before reaching the colon, or whether anything reaches an inflamed segment. The nanoparticle papers from the same laboratory are, read carefully, an argument against free peptide: packaging KPV so that it is released in the colon cut the amount needed by a factor the authors put at 12,000 (Laroui 2010), and the hydrogel-nanoparticle version worked at 16 mcg/kg (Xiao 2017). A capsule of free KPV is the inefficient version of that experiment, at a dose nobody derived from it, in a species nobody has tested.

Nasal and injectable: even less to go on

No study has given KPV nasally to any animal, and nothing about the mechanism makes a nasal dose relevant to the colon or the skin; the nasal charts are a number without a source. Injection has exactly one rodent data point, the single 1 mg/kg dose in the brain-injury study (Schaible 2013), plus the mouse ear-swelling and peritonitis experiments of the 1980s and 2000s, which were not dosing studies and did not establish a human-relevant amount. Injecting a research vial also adds the risks that have nothing to do with KPV: unverified content, endotoxin and no sterility assurance, which our BPC-157 profile describes for the vials these products are usually sold alongside.

The legal reality

There is no legal KPV product in the United States in October 2026. KPV has never been approved anywhere, it is not on FDA's list of substances that compounding pharmacies may use, and it has no USP monograph. It came off FDA's Category 2 safety-risk list on April 15, 2026 after its nomination was withdrawn, and on July 23, 2026 FDA's advisory committee voted 8 to 6 with one abstention to recommend it for the permitted list for wound healing and inflammatory conditions, against the advice of FDA's own staff, who cited the absence of human trial data, inadequate characterization and immunogenicity risk (Kelley Drye 2026). FDA must complete rulemaking before any pharmacy may compound it, and as of October 2026 no proposed rule has been published. A prescription from a clinic does not change that. The legal tracker is updated when FDA acts.

Bottom line

The only KPV dosage chart that is true in 2026 has one row for humans, and it is empty. The animal rows show mice drinking a 100 micromolar solution, a nanoparticle formulation working at 16 mcg/kg, and a single 1 mg/kg injection; the seller rows show numbers borrowed from another peptide. Between them sits the study nobody has done. If you have a gut or skin condition, a dose that has been tested in people exists for the treatments a gastroenterologist or dermatologist can prescribe, and not for this one.

Frequently asked questions

+−What is the correct dosage of KPV peptide?

There is no correct dosage, because KPV has never been given to people in a study. No clinical trial of KPV has been published or registered as of October 2026, so no dose, route, frequency or duration has been tested for safety or effect in humans. Every chart on a seller website is an invention, usually a copy of the BPC-157 chart with the name changed.

+−How much KPV did the mouse studies use?

The Emory group's 2016 colitis-cancer study used 100 micromolar KPV in the water, about 34 milligrams per liter, through repeated colitis cycles (its 2008 colitis study also gave KPV in drinking water for 8 days, at a concentration stated only in the paywalled full paper). By our arithmetic that is roughly 5.5 to 7 milligrams per kilogram a day for a mouse. A nanoparticle study used 16 micrograms per kilogram a day by gavage, but of KPV packaged in colon-targeted nanoparticles, and a brain-injury study used a single 1 milligram per kilogram injection.

+−Is oral KPV absorbed?

In mice, KPV taken in drinking water reduced colitis, and the reason it can work orally is that it is carried into cells by PepT1, the transporter that absorbs small peptides in the small intestine and is switched on in the colon lining during inflammatory bowel disease. Whether a swallowed capsule of free KPV reaches an inflamed human colon in a useful amount has never been measured, and the same laboratory later found that free KPV needed about 12,000 times the concentration of nanoparticle-packaged KPV to do the same job in mice.

+−What is the KPV nasal spray dose?

There is none. No animal or human study has given KPV by the nose, and no mechanism makes a nasal dose relevant to the colon or the skin. The 500 to 1,500 micrograms a day on seller charts is a number without a source.

+−How much KPV do people inject?

Seller charts list 200 to 500 micrograms subcutaneously once a day, with some escalating to 1,500 or 2,000 micrograms for 'severe inflammation'. No human study supports any of it. The only injected rodent dose in the literature is a single 1 milligram per kilogram injection in mice, which by weight scaling would be about 70 milligrams for an adult and by body-surface-area scaling about 5.7 milligrams, roughly 10 to 350 times the chart figures.

+−Can a doctor prescribe KPV at a proper dose?

Not in October 2026. KPV is not FDA-approved and no US pharmacy may compound it: it came off FDA's Category 2 list in April 2026 and FDA's advisory committee recommended it 8-6-1 in July 2026, but no rule has been published. A prescription cannot make a non-compoundable substance compoundable, so there is no pharmacy label, and therefore no labeled dose, for any provider to follow.

Sources

1. StudyDalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-78. (2008)
2. StudyKannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:324-31. (2008)
3. StudyViennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016;2:340-57. (2016)
4. StudyLaroui H et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010;138:843-53. (2010)
5. StudyXiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017;25:1628-40. (2017)
6. StudySchaible EV et al. Single administration of tripeptide alpha-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One 2013;8:e71056. (2013)
7. StudyBonfiglio V et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 2006;83:1366-72. (2006)
8. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know (proposed uses: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing). July 30, 2026. (2026)